Latest Insider Transactions at Calyxt, Inc. (CLXT)
This section provides a real-time view of insider transactions for Calyxt, Inc. (CLXT). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Calyxt, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Calyxt, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 01
2023
|
Michael A. Carr President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
542,233
+21.36%
|
-
|
|
Feb 07
2023
|
William Koschak Chief Financial Officer |
SELL
Other acquisition or disposition
|
Direct |
23,751
-11.18%
|
-
|
|
Jan 01
2023
|
Travis Frey Chief Technology Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
37,573
-16.86%
|
$0
$0.15 P/Share
|
|
Jan 01
2023
|
Michael A. Carr President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
47,877
-11.29%
|
$0
$0.15 P/Share
|
|
Jan 01
2023
|
William Koschak Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
42,570
-16.69%
|
$0
$0.15 P/Share
|
|
Jan 01
2023
|
Debra H Frimerman General Counsel and Secretary |
SELL
Payment of exercise price or tax liability
|
Direct |
35,724
-16.47%
|
$0
$0.15 P/Share
|
|
Sep 19
2022
|
Yves J Ribeill Director |
SELL
Open market or private sale
|
Direct |
30,000
-23.22%
|
$0
$0.24 P/Share
|
|
Jul 27
2022
|
Michael A. Carr President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
4,059
-0.95%
|
$0
$0.22 P/Share
|
|
Mar 24
2022
|
Michael A. Carr President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
368,000
+35.6%
|
-
|
|
Mar 24
2022
|
Travis Frey Chief Technology Officer |
BUY
Grant, award, or other acquisition
|
Direct |
205,650
+39.1%
|
-
|
|
Mar 24
2022
|
Debra H Frimerman General Counsel and Secretary |
BUY
Grant, award, or other acquisition
|
Direct |
200,450
+38.92%
|
-
|
|
Mar 24
2022
|
William Koschak Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
219,700
+37.21%
|
-
|
|
Mar 21
2022
|
Yves J Ribeill Director |
SELL
Open market or private sale
|
Direct |
20,000
-13.4%
|
$20,000
$1.06 P/Share
|
|
Mar 14
2022
|
William Koschak Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,605
-6.86%
|
$2,605
$1.05 P/Share
|
|
Mar 14
2022
|
Debra H Frimerman General Counsel and Secretary |
SELL
Payment of exercise price or tax liability
|
Direct |
2,502
-13.17%
|
$2,502
$1.08 P/Share
|
|
Mar 14
2022
|
Travis Frey Chief Technology Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,173
-11.2%
|
$2,173
$1.08 P/Share
|
|
Aug 30
2021
|
Michael A. Carr President and CEO |
BUY
Open market or private purchase
|
Direct |
10,000
+14.29%
|
$30,000
$3.98 P/Share
|
|
Aug 19
2021
|
William Koschak Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
20,000
+34.48%
|
$60,000
$3.21 P/Share
|
|
Jul 27
2021
|
Michael A. Carr President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
50,000
+50.0%
|
$150,000
$3.65 P/Share
|
|
Jul 27
2021
|
Yves J Ribeill Director |
BUY
Grant, award, or other acquisition
|
Direct |
50,429
+25.26%
|
$151,287
$3.65 P/Share
|
|
Jul 01
2021
|
Yves J Ribeill Director |
BUY
Grant, award, or other acquisition
|
Direct |
12,048
+10.87%
|
$48,192
$4.07 P/Share
|
|
Jun 08
2021
|
Sarah Reiter Chief Business Officer |
BUY
Grant, award, or other acquisition
|
Direct |
11,601
+35.47%
|
-
|
|
Jun 01
2021
|
Yves J Ribeill Director |
BUY
Grant, award, or other acquisition
|
Direct |
11,967
+12.12%
|
-
|
|
May 27
2021
|
Philippe Dumont Director |
BUY
Grant, award, or other acquisition
|
Direct |
7,204
+20.69%
|
-
|
|
May 27
2021
|
Fassberg Jonathan Director |
BUY
Grant, award, or other acquisition
|
Direct |
7,204
+21.18%
|
-
|
|
May 27
2021
|
Christopher J Neugent Director |
BUY
Grant, award, or other acquisition
|
Direct |
7,204
+18.47%
|
-
|
|
May 27
2021
|
Anna Ewa Kozicz Stankiewicz Director |
BUY
Grant, award, or other acquisition
|
Direct |
7,204
+23.02%
|
-
|
|
May 27
2021
|
Yves J Ribeill Director |
BUY
Grant, award, or other acquisition
|
Direct |
18,730
+20.03%
|
-
|
|
May 27
2021
|
Kimberly K. Nelson Director |
BUY
Grant, award, or other acquisition
|
Direct |
7,204
+50.0%
|
-
|
|
May 12
2021
|
Christopher J Neugent Director |
BUY
Open market or private purchase
|
Indirect |
15,000
+50.0%
|
$45,000
$3.95 P/Share
|
|
May 03
2021
|
Yves J Ribeill Director |
BUY
Grant, award, or other acquisition
|
Direct |
9,430
+14.4%
|
-
|
|
Apr 01
2021
|
Yves J Ribeill Director |
BUY
Grant, award, or other acquisition
|
Direct |
16,591
+26.25%
|
-
|
|
Jan 04
2021
|
Daniel F Voytas Chief Science Officer |
SELL
Open market or private sale
|
Direct |
2,513
-100.0%
|
$10,052
$4.13 P/Share
|
|
Dec 31
2020
|
James Blome Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
4,140
-2.17%
|
$16,560
$4.17 P/Share
|
|
Dec 18
2020
|
Daniel F Voytas Chief Science Officer |
SELL
Open market or private sale
|
Direct |
5,026
-66.67%
|
$20,104
$4.75 P/Share
|
|
Dec 01
2020
|
Travis Frey Chief Technology Officer |
BUY
Open market or private purchase
|
Direct |
150
+4.92%
|
$450
$3.79 P/Share
|
|
Nov 02
2020
|
Travis Frey Chief Technology Officer |
BUY
Open market or private purchase
|
Direct |
150
+5.17%
|
$450
$3.26 P/Share
|
|
Oct 16
2020
|
Cellectis S.A. > 10% Shareholder |
BUY
Other acquisition or disposition
|
Direct |
1,250,000
+4.96%
|
$5,000,000
$4.0 P/Share
|
|
Oct 01
2020
|
Travis Frey Chief Technology Officer |
BUY
Open market or private purchase
|
Direct |
150
+5.45%
|
$750
$5.47 P/Share
|
|
Sep 30
2020
|
James Blome Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
4,140
-2.13%
|
$20,700
$5.59 P/Share
|